Fulgent Genetics, Inc.
FLGTHealthcareNASDAQDiagnostics & Research · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Fulgent Genetics, Inc. (FLGT) is listed under Diagnostics & Research. With a market capitalization of $572.6M, it sits in small-cap territory. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Market Cap
$572.6M
Beta
0.89
P/E (TTM)
—
P/E (Fwd)
-13.20
EPS (TTM)
$-2.40
EPS (Fwd)
$-1.53
ROE
-6.9%
ROA
-5.4%
Cash
$276.3M
Total Debt
$10.2M
Free CF
-$105.9M
52W Change
13.4%
Annual Financials
Cash vs Debt
Fulgent Genetics, Inc. holds $276.3M in cash against $10.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$105.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -6.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $619.0M (2022) to $322.7M (2025), a 48% decline worth watching.
With cash comfortably exceeding debt, FLGT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fulgent Genetics, Inc. and its sector.